Last reviewed · How we verify
NCT02157636
A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma
Phase 1 trial testing CPI-0610 in Multiple Myeloma in 30 participants. Completed in 8 November 2016.
8 November 2016
Quick facts
| Lead sponsor | Constellation Pharmaceuticals |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 15 July 2014 |
| Primary completion | 8 November 2016 |
| Estimated completion | 8 November 2016 |
Drugs / interventions tested
- CPI-0610 — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Constellation Pharmaceuticals — full company profile →
Who can join
18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated multiple myeloma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.
Cheng Y, He C, Wang M, Ma X, et al · · 2019 · cited 760× · PMID 31871779 · DOI 10.1038/s41392-019-0095-0 -
Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y, Tao L, Qiu J, Xu J, et al · · 2024 · cited 379× · PMID 38763973 · DOI 10.1038/s41392-024-01823-2 -
Therapeutic targeting of "undruggable" MYC.
Llombart V, Mansour MR. · · 2022 · cited 349× · PMID 34942444 · DOI 10.1016/j.ebiom.2021.103756 -
Epigenetics in cancer stem cells.
Toh TB, Lim JJ, Chow EK. · · 2017 · cited 286× · PMID 28148257 · DOI 10.1186/s12943-017-0596-9 -
Achieving clinical success with BET inhibitors as anti-cancer agents.
Shorstova T, Foulkes WD, Witcher M. · · 2021 · cited 272× · PMID 33723398 · DOI 10.1038/s41416-021-01321-0 -
Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity.
Wainwright EN, Scaffidi P. · · 2017 · cited 250× · PMID 28718414 · DOI 10.1016/j.trecan.2017.04.004 -
Drug Discovery Targeting Bromodomain-Containing Protein 4.
Liu Z, Wang P, Chen H, Wold EA, et al · · 2017 · cited 234× · PMID 28195723 · DOI 10.1021/acs.jmedchem.6b01761 -
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
Alqahtani A, Choucair K, Ashraf M, Hammouda DM, et al · · 2019 · cited 198× · PMID 30906568 · DOI 10.4155/fsoa-2018-0115
Verify or expand the search:
- PubMed search for NCT02157636
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CPI-0610
Trials testing the same drug.
- NCT02986919 — Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors · Phase 2 · withdrawn
- NCT01949883 — A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma · Phase 1 · completed
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other Constellation Pharmaceuticals trials
Trials by the same sponsor.
- NCT05391022 — Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies · Phase 1 · completed
- NCT03525795 — ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors · Phase 1 · completed
- NCT03480646 — ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer · Phase 1, PHASE2 · completed
- NCT02158858 — A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignanc · Phase 1, PHASE2 · completed
- NCT01949883 — A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02157636 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Constellation Pharmaceuticals
- Last refreshed: 18 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02157636.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing